Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase IIa results for i.v. cannabinor in postoperative pain

April 26, 2007

Miraxion fails to meet endpoints in phase III Huntington's studies

April 26, 2007

New data confirm oral bioavailability of AL-309

April 26, 2007

NS-2359 begins second phase II study for depression

April 26, 2007

Two phase I studies of PTC-124 in healthy adults completed

April 26, 2007

Synosia in-licenses rufinamide for anxiety disorders and bipolar mood disorders

April 25, 2007

Phase IIa biomarker study investigates HF-0220 in mild to moderate Alzheimer's

April 25, 2007

New diagnostic agents for schizophrenia reported by Merck

April 24, 2007

ADX-10059 meets primary endpoint in migraine study

April 24, 2007

Keppra effective as adjunctive therapy in partial onset seizures in young children

April 23, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...